Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sumitomo Dainippon Pharma Co. Ltd.

Division of Sumitomo Chemical Co.
www.ds-pharma.com

Latest From Sumitomo Dainippon Pharma Co. Ltd.

Exscientia Links With Scripp Research’s Calibr To Apply AI To COVID-19

A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.

Artificial Intelligence Coronavirus COVID-19

Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma

Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.

Japan Approvals

Dainippon Lays Out R&D Table Ahead Of Latuda Challenges

Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.

Clinical Trials Innovation

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Financing Business Strategies
See All

Company Information

UsernamePublicRestriction

Register